Lead Product(s) : 3,4-Methylenedioxymethamphetamine HCl
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : MAPS
Deal Size : $0.2 million
Deal Type : Funding
MAPS Awards Grant for Pilot MDMA-assisted Massed Exposure Therapy Trial
Details : The funding will be used for a pilot study examining 3,4-methylenedioxymethamphetamine (MDMA)-assisted massed exposure therapy for post-traumatic stress disorder.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
August 27, 2024
Lead Product(s) : 3,4-Methylenedioxymethamphetamine HCl
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : MAPS
Deal Size : $0.2 million
Deal Type : Funding
Lead Product(s) : 3,4-Methylenedioxymethamphetamine HCl
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Dose-Response Study of MDMA-assisted Psychotherapy in People With PTSD
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 15, 2013
Lead Product(s) : 3,4-Methylenedioxymethamphetamine HCl
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable